促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义  

Mechanism of thyroid-stimulating immunoglobulin in Gravesdisease recurrence and clinical significance

作　　者：杨卫芳[1] 徐宏[1] 刘元涛 赵蕙琛 YANG Weifang;XU Hong;LIU Yuantao;ZHAO Huichen(Department of Endocrinology,Qingdao Municipal Hospital,Qingdao 266011,Shandong,China;Department of Endocrinology,Qilu Hospital(Qingdao)of Shandong University,Qingdao 266035,Shandong,China)

机构地区：[1]青岛市市立医院内分泌科,山东青岛266011 [2]山东大学齐鲁医院(青岛)内分泌科,山东青岛266035

出　　处：《山东大学学报(医学版)》2025年第4期116-121,共6页Journal of Shandong University:Health Sciences

基　　金：山东省医药卫生科技发展计划(202203060248);青岛市医药卫生科研指导项目(2022-WJZD003)。

摘　　要：Graves病是最常见的自身免疫性甲状腺功能亢进症,其50%以上的高复发率显著影响患者的生活质量。促甲状腺激素受体抗体(thyrotrophin receptor antibody,TRAb)是Graves病的特异性生物标志物,影响疾病的诊断、治疗和复发预测。TRAb的水平与疾病活动性及复发风险高度相关,是治疗停药的主要指标之一。然而,TRAb参与Graves病发病的具体机制及其临床应用仍存在许多问题。本文旨在系统探讨TRAb在Graves病复发中的指导作用,分析其可能机制及临床意义,以期为临床实践提供参考。Gravesdisease,the leading cause of autoimmune hyperthyroidism,has a recurrence rate exceeding 50%,greatly impacting patientsquality of life.Thyrotrophin receptor antibody(TRAb)is a specific biomarker for diagnosing,treating,and predicting the recurrence of Gravesdisease.TRAb levels strongly correlate with disease activity and recurrence risk,and are key for deciding on drug withdrawal.However,the specific mechanism and clinical application of TRAb in Gravesdisease still remain unclear.This paper investigates the role of TRAb in Gravesdisease recurrence,so as to explore its mechanisms and clinical importance to inform clinical practice.

关 键 词：促甲状腺激素受体抗体 甲状腺刺激抗体 GRAVES病 复发 预后 

分 类 号：R581.1[医药卫生—内分泌]